PL2900263T3 - Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (GDF-15) - Google Patents
Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (GDF-15)Info
- Publication number
- PL2900263T3 PL2900263T3 PL13776433T PL13776433T PL2900263T3 PL 2900263 T3 PL2900263 T3 PL 2900263T3 PL 13776433 T PL13776433 T PL 13776433T PL 13776433 T PL13776433 T PL 13776433T PL 2900263 T3 PL2900263 T3 PL 2900263T3
- Authority
- PL
- Poland
- Prior art keywords
- gdf
- growth
- monoclonal antibodies
- differentiation factor
- differentiation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186185 | 2012-09-26 | ||
| EP13776433.8A EP2900263B1 (en) | 2012-09-26 | 2013-09-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| PCT/EP2013/070127 WO2014049087A1 (en) | 2012-09-26 | 2013-09-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2900263T3 true PL2900263T3 (pl) | 2019-10-31 |
Family
ID=46888333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13776433T PL2900263T3 (pl) | 2012-09-26 | 2013-09-26 | Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (GDF-15) |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20150239968A1 (pl) |
| EP (2) | EP2900263B1 (pl) |
| JP (4) | JP2015532271A (pl) |
| KR (1) | KR101838786B1 (pl) |
| CN (1) | CN104853775B (pl) |
| AU (2) | AU2013322628B2 (pl) |
| CA (1) | CA2886207C (pl) |
| CY (1) | CY1121832T1 (pl) |
| DK (1) | DK2900263T3 (pl) |
| ES (1) | ES2742287T3 (pl) |
| HR (1) | HRP20191326T1 (pl) |
| HU (1) | HUE044363T2 (pl) |
| IL (2) | IL237828B (pl) |
| LT (1) | LT2900263T (pl) |
| NZ (1) | NZ706189A (pl) |
| PL (1) | PL2900263T3 (pl) |
| PT (1) | PT2900263T (pl) |
| RS (1) | RS59045B1 (pl) |
| SG (1) | SG11201502279YA (pl) |
| SI (1) | SI2900263T1 (pl) |
| SM (1) | SMT201900457T1 (pl) |
| TR (1) | TR201910744T4 (pl) |
| WO (1) | WO2014049087A1 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201502279YA (en) | 2012-09-26 | 2015-04-29 | Julius Maximilians Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| AU2014352843B2 (en) | 2013-11-21 | 2020-03-05 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| PL3122775T3 (pl) * | 2014-03-26 | 2020-05-18 | Julius-Maximilians-Universität Würzburg | Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu |
| GB2524553C (en) * | 2014-03-26 | 2017-07-19 | Julius-Maximilians-Universitãt Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| GB2524552B (en) * | 2014-03-26 | 2017-07-12 | Julius-Maximilians-Universitãt Wurzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| WO2015196145A1 (en) * | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| WO2016019368A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| SMT202300017T1 (it) * | 2015-10-02 | 2023-03-17 | Univ Wuerzburg J Maximilians | Terapia in combinazione usando inibitori del fattore della crescita e della differenziazione 15 (gdf-15) umano e bloccanti del punto di controllo immunitario |
| KR102621034B1 (ko) | 2015-10-02 | 2024-01-03 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 면역 체크포인트 차단제를 이용한 치료의 임상적인 경과를 예측하기 위한 진단 마커로서의 gdf-15 |
| GB201517528D0 (en) | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| ITUB20154769A1 (it) * | 2015-11-04 | 2017-05-04 | Centro Di Riferimento Oncologico Cro Irccs Aviano | Anticorpo monoclonale anti-BARF1 |
| JP6829444B2 (ja) * | 2016-02-29 | 2021-02-10 | 公立大学法人横浜市立大学 | 去勢抵抗性前立腺癌を検出する方法及び検出試薬 |
| AU2017228489A1 (en) * | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| AU2017241161B2 (en) | 2016-03-31 | 2022-05-26 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| EP3448887A1 (en) * | 2016-04-27 | 2019-03-06 | Novartis AG | Antibodies against growth differentiation factor 15 and uses thereof |
| CN107782900A (zh) * | 2016-08-31 | 2018-03-09 | 朱海燕 | 人生长分化因子‑15的检测试纸组件 |
| KR102010652B1 (ko) * | 2017-08-21 | 2019-08-13 | 서울대학교병원 | 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법 |
| WO2021111636A1 (ja) * | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗ｇｄｆ１５抗体 |
| KR20230107309A (ko) | 2020-11-10 | 2023-07-14 | 카탈임 게엠베하 | 항-gdf15 항체 및 암 치료용 투여 용법 |
| CN112698042A (zh) * | 2020-12-17 | 2021-04-23 | 北京赛诺浦生物技术有限公司 | 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用 |
| AU2022251923A1 (en) | 2021-03-31 | 2023-11-16 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| CN113252905A (zh) * | 2021-05-12 | 2021-08-13 | 北京赛诺浦生物技术有限公司 | 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用 |
| EP4384545A1 (en) | 2021-08-10 | 2024-06-19 | BYOMass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| CN113702647B (zh) * | 2021-08-31 | 2024-03-15 | 普十生物科技(北京)有限公司 | 人生长分化因子15即时检测试剂盒、其制备方法及其应用 |
| EP4452316A1 (en) | 2021-12-22 | 2024-10-30 | BYOMass Inc. | Targeting gdf15-gfral pathway |
| EP4524158A4 (en) * | 2022-05-09 | 2025-12-17 | Staidson Beijing Biopharmaceuticals Co Ltd | Antibody that specifically recognizes gdf15 and use thereof |
| CN116813742A (zh) * | 2022-11-22 | 2023-09-29 | 杭州博茵生物技术有限公司 | 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用 |
| CN116462757A (zh) * | 2023-03-24 | 2023-07-21 | 科兴生物制药股份有限公司 | Gdf15的单域抗体及其应用 |
| CN118515761B (zh) * | 2024-07-19 | 2024-10-29 | 北京志道生物科技有限公司 | 一种gdf-15纳米抗体及其应用 |
| CN118878677A (zh) * | 2024-09-29 | 2024-11-01 | 江苏凯基生物技术股份有限公司 | 一种IgM亚型单克隆抗体及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| ES2275513T3 (es) | 1999-05-17 | 2007-06-16 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta. |
| AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| SI2311873T1 (sl) | 2004-01-07 | 2018-12-31 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specifična monoklonska protitelesa in njihova uporaba |
| DK2929891T3 (da) | 2004-04-13 | 2020-05-11 | St Vincents Hospital Sydney Ltd | Fremgangsmåde til modulering af appetitten |
| EP2783698A1 (en) | 2007-08-16 | 2014-10-01 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
| US20100266707A1 (en) | 2007-10-09 | 2010-10-21 | Samuel Norbert Breit | Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| NZ591484A (en) | 2008-09-29 | 2012-09-28 | Roche Glycart Ag | Antibodies against human il 17 and uses thereof |
| US20120309697A1 (en) * | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| CN101852804B (zh) * | 2010-03-29 | 2013-06-12 | 中国医学科学院病原生物学研究所 | Gdf15蛋白的抗体的新用途 |
| CA2817964C (en) * | 2010-11-17 | 2018-06-12 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN102321173B (zh) * | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
| EP2807266B1 (en) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| SG11201502279YA (en) * | 2012-09-26 | 2015-04-29 | Julius Maximilians Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| CN105073133B (zh) | 2012-12-21 | 2021-04-20 | Aveo制药公司 | 抗gdf15抗体 |
| SMT202300017T1 (it) * | 2015-10-02 | 2023-03-17 | Univ Wuerzburg J Maximilians | Terapia in combinazione usando inibitori del fattore della crescita e della differenziazione 15 (gdf-15) umano e bloccanti del punto di controllo immunitario |
| KR102621034B1 (ko) * | 2015-10-02 | 2024-01-03 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 면역 체크포인트 차단제를 이용한 치료의 임상적인 경과를 예측하기 위한 진단 마커로서의 gdf-15 |
| JP7155403B2 (ja) * | 2018-08-20 | 2022-10-18 | ファイザー・インク | 抗ｇｄｆ１５抗体、組成物および使用の方法 |
-
2013
- 2013-09-26 SG SG11201502279YA patent/SG11201502279YA/en unknown
- 2013-09-26 ES ES13776433T patent/ES2742287T3/es active Active
- 2013-09-26 PT PT13776433T patent/PT2900263T/pt unknown
- 2013-09-26 JP JP2015533588A patent/JP2015532271A/ja active Pending
- 2013-09-26 US US14/431,281 patent/US20150239968A1/en not_active Abandoned
- 2013-09-26 NZ NZ706189A patent/NZ706189A/en unknown
- 2013-09-26 CA CA2886207A patent/CA2886207C/en active Active
- 2013-09-26 HR HRP20191326 patent/HRP20191326T1/hr unknown
- 2013-09-26 TR TR2019/10744T patent/TR201910744T4/tr unknown
- 2013-09-26 RS RS20190923A patent/RS59045B1/sr unknown
- 2013-09-26 PL PL13776433T patent/PL2900263T3/pl unknown
- 2013-09-26 SM SM20190457T patent/SMT201900457T1/it unknown
- 2013-09-26 DK DK13776433.8T patent/DK2900263T3/da active
- 2013-09-26 AU AU2013322628A patent/AU2013322628B2/en active Active
- 2013-09-26 EP EP13776433.8A patent/EP2900263B1/en active Active
- 2013-09-26 KR KR1020157010334A patent/KR101838786B1/ko active Active
- 2013-09-26 WO PCT/EP2013/070127 patent/WO2014049087A1/en not_active Ceased
- 2013-09-26 CN CN201380061148.XA patent/CN104853775B/zh active Active
- 2013-09-26 HU HUE13776433 patent/HUE044363T2/hu unknown
- 2013-09-26 LT LTEP13776433.8T patent/LT2900263T/lt unknown
- 2013-09-26 EP EP19177843.0A patent/EP3590537A1/en active Pending
- 2013-09-26 SI SI201331512T patent/SI2900263T1/sl unknown
-
2015
- 2015-03-19 IL IL237828A patent/IL237828B/en active IP Right Grant
-
2017
- 2017-05-26 AU AU2017203523A patent/AU2017203523B2/en active Active
- 2017-07-31 JP JP2017147489A patent/JP6670275B2/ja active Active
-
2018
- 2018-03-12 US US15/918,841 patent/US10781251B2/en active Active
-
2019
- 2019-07-24 CY CY20191100787T patent/CY1121832T1/el unknown
- 2019-10-24 JP JP2019193124A patent/JP7270522B2/ja active Active
-
2020
- 2020-08-11 US US16/990,929 patent/US11891436B2/en active Active
- 2020-09-16 IL IL277392A patent/IL277392A/en unknown
-
2021
- 2021-08-11 JP JP2021131153A patent/JP2022017219A/ja active Pending
-
2023
- 2023-12-21 US US18/392,926 patent/US20240239882A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277392A (en) | Monoclonal antibodies to growth and differentiation factor 15 | |
| IL233725A0 (en) | Growth and differentiation factor 15 (gdf-15) polypeptides | |
| IL243749A0 (en) | Growth differentiation factor templates 15 | |
| IL256716A (en) | Antibodies against hla–b*27 and their uses | |
| ZA201608660B (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| GB201114858D0 (en) | Anti-nerve growth factor antibodies and methods of using the same | |
| GB2504887B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
| GB2504888B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
| GB201517547D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| EP2775305A4 (en) | FLUORO-IMMUNOLOGY ASSAY METHOD USING A POLYPEPTIDE COMPLEX CONTAINING A VARIABLE FLUOROMARCATED ANTIBODY REGION | |
| HUE037613T2 (hu) | Anti-TLR4 antitestek és azok felhasználása | |
| IL238366B (en) | Antibodies to interleukin-6 and their uses | |
| EP2650367A4 (en) | HUMAN MONOCLONAL ANTIBODY | |
| HUS2200012I1 (hu) | Idegi növekedési faktor elleni ellenanyagok és eljárások elõállításukra és alkalmazásukra | |
| GB201519606D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| GB2505352B (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |